Regulation Of A Novel Xenopus Polo-Like Kinase 1 Substrate

新型非洲爪蟾 Polo 样激酶 1 底物的调节

基本信息

  • 批准号:
    8014988
  • 负责人:
  • 金额:
    $ 13.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-02-01 至 2013-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Polo-like kinase 1 (PLK1) plays a pivotal role at multiple steps of mitosis. Recently, PLK1 was implicated as an oncogene and has emerged as a potential target for anti-cancer drugs. Although significant progress has been made towards the understanding of the roles of PLK1 in cell cycle control, the molecular mechanisms by which it executes its functions during some important mitotic events remains elusive, largely due to the lack of identified physiological substrates for PLK1. This applicant presents preliminary data that focuses on a novel substrate for Xenopus polo- like kinase 1 (PLX1). The substrate has been identified and characterized as a deubiquitinase, whose mammalian homologue specifically modifies histone and affects cell division. The long- term goal of this proposed research is to define a novel mechanism by which PLX1 regulates the progression of cell cycle through the phosphorylation of this deubiquitinase. For the purposes of this application, the immediate or short-term goal is to clarify PLX1 regulation of the novel substrate and to determine the impact of such phosphorylation on the deubiquitinase. Since cyclin B/Cdk1 (MPF) is also suggested as a phosphorylating kinase for the deubiquitinase, our hypothesis is that PLX1 regulates the activity and possibly the localization of this deubiquitinase in vivo in coordination with MPF, which in turn, affects the progression of cell cycle. The hypothesis will be tested through the activities associated with following objectives: (1) Identify the main sites in the deubiquitinase phosphorylated by PLX1 and MPF; (2) Determine the impact of PLX1 phosphorylation on activity and localization of this substrate. The possibility that PLX1 phosphorylation activates the deubiquitinase and changes its localization will be examined; and (3) Determine whether phosphorylation of the substrate by PLX1 requires MPF priming. In many cases, PLX1 phosphorylation requires the priming of a PLX1 substrate by a distinct kinase in order to generate a binding site for polo box domain, a unique structure in the polo-like kinase family. The proposed studies are expected to result in accumulation of further preliminary data and lead to the submission of a full research proposal by the end of the project. PUBLIC HEALTH RELEVANCE: Polo-like kinase 1 is a key cell cycle regulator and has recently emerged as a promising target for anti-cancer drugs. This application proposes to study the regulation of a novel substrate for polo-like kinase 1. The study is expected to reveal a new mechanism of cell cycle control and may also provide a foundation for developing innovative strategies for treating human diseases such as cancer.
描述(由申请人提供):Polo样激酶1(PLK 1)在有丝分裂的多个步骤中发挥关键作用。最近,PLK 1被认为是一种致癌基因,并已成为抗癌药物的潜在靶点。虽然PLK 1在细胞周期控制中的作用的理解已经取得了重大进展,但它在一些重要的有丝分裂事件中执行其功能的分子机制仍然难以捉摸,这主要是由于缺乏PLK 1的识别生理底物。本申请人提供了集中于爪蟾波罗样激酶1(PLX 1)的新型底物的初步数据。该底物已被鉴定和表征为去泛素化酶,其哺乳动物同源物特异性修饰组蛋白并影响细胞分裂。这项研究的长期目标是确定一种新的机制,PLX 1通过磷酸化这种去泛素化酶来调节细胞周期的进展。为了本申请的目的,直接或短期目标是阐明PLX 1对新底物的调节,并确定这种磷酸化对去泛素化酶的影响。由于细胞周期蛋白B/Cdk 1(MPF)也被认为是去泛素化酶的磷酸化激酶,我们的假设是PLX 1与MPF协同调节该去泛素化酶的活性和可能的体内定位,从而影响细胞周期的进展。该假说将通过与以下目标相关的活动进行检验:(1)确定PLX 1和MPF磷酸化的去泛素化酶的主要位点;(2)确定PLX 1磷酸化对该底物活性和定位的影响。将检查PLX 1磷酸化激活去泛素化酶并改变其定位的可能性;和(3)确定PLX 1对底物的磷酸化是否需要MPF引发。在许多情况下,PLX 1磷酸化需要通过不同的激酶引发PLX 1底物,以产生polo box结构域的结合位点,polo box结构域是polo样激酶家族中的独特结构。预计拟议的研究将积累更多的初步数据,并在项目结束时提交一份完整的研究提案。 Polo样激酶1是一种关键的细胞周期调节因子,最近已成为抗癌药物的一个有前途的靶点。本申请提出研究polo样激酶1的新型底物的调节。这项研究有望揭示细胞周期控制的新机制,也可能为开发治疗癌症等人类疾病的创新策略提供基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Junjun Liu其他文献

Junjun Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Junjun Liu', 18)}}的其他基金

Usp16-Mediated Histone H2A Deubiquitination Regulates Breast Cancer Cell Invasion
Usp16 介导的组蛋白 H2A 去泛素化调节乳腺癌细胞侵袭
  • 批准号:
    10377552
  • 财政年份:
    2019
  • 资助金额:
    $ 13.64万
  • 项目类别:
Usp16-Mediated Histone H2A Deubiquitination Regulates Breast Cancer Cell Invasion
Usp16 介导的组蛋白 H2A 去泛素化调节乳腺癌细胞侵袭
  • 批准号:
    9888396
  • 财政年份:
    2019
  • 资助金额:
    $ 13.64万
  • 项目类别:
Regulation Of A Novel Xenopus Polo-Like Kinase 1 Substrate
新型非洲爪蟾 Polo 样激酶 1 底物的调节
  • 批准号:
    8212250
  • 财政年份:
    2010
  • 资助金额:
    $ 13.64万
  • 项目类别:
Regulation Of A Novel Xenopus Polo-Like Kinase 1 Substrate
新型非洲爪蟾 Polo 样激酶 1 底物的调节
  • 批准号:
    7762116
  • 财政年份:
    2010
  • 资助金额:
    $ 13.64万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 13.64万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 13.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 13.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 13.64万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 13.64万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 13.64万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 13.64万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 13.64万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 13.64万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 13.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了